epatide (15 mg) across all regimens exhibiting marked weight−lowering effects (monotherapy: MD −9.40 kg; plus insulin: MD −8.10 kg) and the semaglutide 1 mg plus insulin regimen also having robust efficacy (MD −5.00 kg [95% CrI −7.00 to −3.00]), while the liraglutide 0.6 mg monotherapy regimen even showed a trend toward weight gain (MD 0.37 kg [95% CrI −2.10 to 2.90]) (see Supplementary Appendix 14 ). 4 Discussion This network meta-analysis shows that IBTs deliver comprehensive benefits for T2DM.
← all excerpts
Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.
1
—
—